Navigation Links
MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
Date:8/18/2008

ted state-of- art chemistry and biology facility for drug discovery and development activities to advance its next-generation antimicrobial products.

About Multi-Drug Resistance and MRSA

Modern antimicrobials (antibiotics and related pharmaceuticals) have substantially reduced the threat posed by infectious diseases and contributed to a dramatic drop in mortality rates over the past 30 years. However, due to widespread use of existing drugs in the community and hospital environment, pathogenic bacteria resistant to current antimicrobial therapies have evolved and become ubiquitous, presenting a global health threat. The World Health Organization has set forth a mandate to combat this growing problem and encouraged an urgent action of the member countries. MicuRx is addressing this need directly by developing best-in-class antimicrobials targeting multi- drug resistant bacteria.

About MicuRx Pharmaceuticals, Inc.

MicuRx is discovering and developing next-generation antibacterial and antifungal products. By applying designer modifications to validated antibiotics, MicuRx intends to improve overall pharmacological properties of antimicrobial drugs in order to overcome antibiotic resistance, increase the antibacterial spectrum, improve the dosing regimen, or reduce adverse side effects. The company has research and development facilities in San Francisco Bay Area and ZhangJiang High-Tech Park in Shanghai, China.


'/>"/>
SOURCE MicuRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
2. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
3. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
4. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... (PRWEB) June 18, 2013 Demanding industrial ... Lenses engineered of synthetic Sapphire and Glass Ball Lenses, ... from Swiss Jewel Company , of Philadelphia , ... expanding and collimating the light beams without the need ... clarity and natural durability (9 mohs) make it the ...
(Date:6/18/2013)... 2013 RegeneCure announced today ... AMCA Guided Bone Regeneration (GBR) Dental Membrane as a bone ... common problem encountered when patients have a tooth replaced with ... to house the implant. Consequently there is often a need ... natural bone regenerates. The bone substitute material, in turn, needs ...
(Date:6/18/2013)... ALBANY, N.Y. , June 18, 2013 /PRNewswire/ ... that its Burlington, Mass. , ... U.S. Drug Enforcement Administration (DEA) registration to handle ... represents the DEA,s acknowledgement of Burlington,s ... inventory control and documentation. (Logo: ...
(Date:6/18/2013)... Canada (PRWEB) June 18, 2013 ... oversight of pharmaceutical advertising and promotion, and review ... Viewers will learn how to apply these principles ... examples:, ,     The fundamentals on FDA ... and promotional labeling ,     Assessing traditional and ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2
... TROMS0, Norway and SEOUL, Korea, June 19 ... KAEL-GemVax,today announced the signing of a collaborative agreement to ... for the treatment of,cancer. , ... CEO Jay,Sangjae Kim, "We are delighted to announce this ...
... research from Cincinnati Children,s Hospital Medical Center highlights the critical ... embryonic development on formation of a normal heart and skull. ... Proceedings of the National Academy of Sciences , a ... the gene/protein SHP2 interferes with the normal developmental activity of ...
... Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biopharmaceutical ... HIV-1 (Human Immunodeficiency Virus), and other infectious agents, announced ... cooperative arrangement with Cook County Board President Todd H. ... County Health and Hospitals Systems Board ("Health System"); and ...
Cached Biology Technology:Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy 2Scientists identify gene vital to early embryonic cells forming a normal heart and skull 2GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 2GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 3GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 4GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 5
(Date:6/18/2013)... chemical modification of DNA and this modification can ... sequence. Until now, scientists believed that this epigenetic ... Today, a team of researchers from the University ... Louis-Jeantet Professor at the Faculty of Medicine, reveals ... that DNA methylation may play both a passive ...
(Date:6/17/2013)... a new virus in patients with severe brain infections ... the virus is responsible for the symptoms of disease. ... 28 out of 644 patients with severe brain infections ... in any of the 122 patients with non-infectious brain ... and central nervous system are often fatal and patients ...
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
Breaking Biology News(10 mins):The secret of DNA methylation 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
... 12 collaborating institutions have been awarded $24 million in ... for Environmental Implications of Nanotechnology (UC CEIN), which will ... The center, to be housed ... campus, will explore the impact of nanomaterials on life ...
... DURHAM, NC--The National Science Foundation (NSF) and the Environmental ... the Center for Environmental Implications of NanoTechnology (CEINT) to ... Nanoparticles are as much as a million times smaller ... properties compared with larger objects made from the same ...
... University of North Carolina at Chapel Hill School of Medicine ... insulin, the hormone used to treat diabetes. The ... a cure for the millions of people affected by the ... into pluripotent stem cells, or cells that can give rise ...
Cached Biology News:UCLA, partners establish new center on environmental effects of nanotechnology 2UCLA, partners establish new center on environmental effects of nanotechnology 3UCLA, partners establish new center on environmental effects of nanotechnology 4Duke to lead new NSF, EPA center to study the environmental implications of nanotechnology 2Duke to lead new NSF, EPA center to study the environmental implications of nanotechnology 3UNC scientists turn human skin cells into insulin-producing cells 2
... new Vivaspin 2 bridges the gap between ... concentrators. This device combines the speed of ... surface and membrane area for superior recoveries ... a choice of PES, Cellulose Triacetate membranes, ...
... II) is involved in translation initiation. PHAS-II ... proteins bind to eIF-4E, the mRNA cap-binding ... in vitro and in cells. Phosphorylation in ... complexes. This allows eIF-4E to bind to ...
Goat polyclonal to Lipocalin 2...
... Vesicular Monoamine Transporter 2 (VMAT2). An antibody ... a major band at ~55 kDa in ... and not in wild type cells (2). ... molecular weight, were also detected and remain ...
Biology Products: